Orexigen re-acquires US rights to Contrave (naltrexone HCl / bupropion HCl extended release) to treat obesity in United States from Takeda
Orexigen Therapeutics announced it has entered into an agreement with Takeda to acquire the United States rights to Contrave (naltrexone HCl / bupropion HCl extended release). Upon completion of the acquisition, Orexigen will own all rights to Contrave in nearly all global territories. The acquisition of Contrave by Orexigen is possible as a result of Takeda's realignment of resources behind its recently announced strategic therapeutic areas of focus, and Orexigen's desire to take on more direct responsibility for the Company's flagship product.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins